New antibody treatment tested for rare blood cancer

NCT ID NCT06510491

First seen Mar 19, 2026 · Last updated Apr 21, 2026 · Updated 5 times

Summary

This study is testing whether an antibody drug called epcoritamab can help control Waldenstrom Macroglobulinemia, a rare blood cancer, in patients who have already received previous treatments. The trial will enroll 20 participants to measure how well their cancer responds to this experimental therapy. Researchers will track whether the treatment reduces cancer activity and how long the benefits last.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.